文献速递膀胱癌与上尿路尿路上皮癌

Xpert膀胱癌监测尿液标志物指导高级别非肌层浸润性膀胱癌膀胱镜检:DaBlaCa-15随机对照试验

Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial.
PubMed 文献 · Eur Urol · 2025-04-25

DaBlaCa-15随机非劣效试验评估交替使用Xpert膀胱癌监测(XBCM)尿液标志物与膀胱镜检减少高级别NMIBC随访膀胱镜次数。干预组与对照组高级别复发风险差0.08%(95%CI -7.2%至7.4%),膀胱镜总数分别为445和1029次,XBCM漏检2例pTa高级别复发。交替策略减少膀胱镜次数且未影响复发检出,长期肿瘤学安全性需延长随访验证。

要点

  • 交替XBCM与膀胱镜检使随访膀胱镜次数从1029次降至445次
  • 高级别复发风险差0.08%(95%CI -7.2%至7.4%),两组相当
  • XBCM漏检2例pTa高级别复发,长期安全性待验证

核心结论

  • 交替膀胱镜与XBCM减少高级别NMIBC随访膀胱镜次数且未影响复发检出。
  • 该策略长期肿瘤学安全性需更长随访验证。

研究设计与样本

  • 随机非劣效试验,干预组交替XBCM与膀胱镜检,对照组每次随访均行膀胱镜检。
  • 主要结局为两组高级别NMIBC、肌层浸润性膀胱癌或转移性尿路上皮癌的无复发生存风险比较。

主要发现

  • 共检出43例高级别复发,干预组22例,对照组21例。
  • 两组高级别复发风险差0.08%(95%CI -7.2%至7.4%)。
  • XBCM漏检2例pTa高级别复发。
  • 膀胱镜次数:对照组1029次,干预组445次。
  • 观察到预期阳性效应,XBCM阳性先于膀胱镜可见复发。

临床怎么用

  • 高级别NMIBC随访中可考虑交替XBCM与膀胱镜检以减少膀胱镜次数。
  • 需注意XBCM可能漏检pTa高级别复发,长期安全性待验证。

局限性

  • 两组复发率低于预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Urinary biomarker tests have long been suggested as a noninvasive alternative to current cystoscopy-based follow-up of high-grade non-muscle-invasive bladder cancer (NMIBC) to reduce both morbidity and costs. However, the clinical impact of urinary biomarker tests remains uncertain owing to a lack of randomized trials. METHODS: In this randomized noninferiority trial, we evaluated the impact of alternating a urinary biomarker test (Xpert Bladder Cancer Monitor, XBCM) with cystoscopy in the intervention arm as a method for reducing the number of cystoscopies during follow-up of patients with high-grade NMIBC. Patients in the control arm underwent cystoscopy at all follow-up visits. The primary outcome was comparison of the risk of recurrence-free survival in terms of high-grade NMIBC, muscle-invasive bladder cancer, or metastatic urothelial carcinoma between the study arms. KEY FINDINGS AND LIMITATIONS: In total, 43 high-grade recurrences were detected, 22 in the intervention arm and 21 in the control arm. The risk difference for high-grade recurrence between the study arms was 0.08% (95% confidence interval -7.2% to 7.4%). Two pTa high-grade recurrences were missed by the XBCM test. The number of cystoscopies performed was 1029 cystoscopies in the control arm and 445 in the intervention arm. An anticipatory positive effect was observed, with XBCM positivity observed before recurrences were visible on cystoscopy. The findings are limited by a lower-than-expected rate of recurrence in both study arms. CONCLUSIONS AND CLINICAL IMPLICATIONS: Alternating cystoscopy with XBCM reduced the number of follow-up cystoscopies for high-grade NMIBC without affecting detection of any recurrence. The long-term oncological safety of this strategy needs to be validated over longer follow-up.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Dreyer T, Brandt S, Fabrin K, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. 2025. PMID: 40280776. doi:10.1016/j.eururo.2025.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。